Frankfurt - Delayed Quote EUR

Beximco Pharmaceuticals Limited (R2WA.F)

Compare
0.4080 0.0000 (0.00%)
At close: December 27 at 8:20:01 AM GMT+1
Loading Chart for R2WA.F
DELL
  • Previous Close 0.4080
  • Open 0.4080
  • Bid 0.3960 x 3669800
  • Ask 0.4640 x 3183100
  • Day's Range 0.4080 - 0.4080
  • 52 Week Range 0.2360 - 0.4920
  • Volume 417
  • Avg. Volume 1,098
  • Market Cap (intraday) 288.237M
  • Beta (5Y Monthly) 0.62
  • PE Ratio (TTM) 3.71
  • EPS (TTM) 0.1100
  • Earnings Date Jan 28, 2025 - Feb 3, 2025
  • Forward Dividend & Yield 0.03 (8.36%)
  • Ex-Dividend Date Nov 22, 2024
  • 1y Target Est --

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It offers its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.

www.beximcopharma.com

1,122

Full Time Employees

June 30

Fiscal Year Ends

Recent News: R2WA.F

View More

Performance Overview: R2WA.F

Trailing total returns as of 12/28/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

R2WA.F
2.24%
MSCI WORLD
18.50%

1-Year Return

R2WA.F
0.03%
MSCI WORLD
18.25%

3-Year Return

R2WA.F
59.30%
MSCI WORLD
15.99%

5-Year Return

R2WA.F
13.22%
MSCI WORLD
58.80%

Compare To: R2WA.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: R2WA.F

View More

Valuation Measures

As of 12/23/2024
  • Market Cap

    287.98M

  • Enterprise Value

    316.66M

  • Trailing P/E

    3.85

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.51

  • Price/Book (mrq)

    0.46

  • Enterprise Value/Revenue

    0.89

  • Enterprise Value/EBITDA

    4.56

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.13%

  • Return on Assets (ttm)

    7.48%

  • Return on Equity (ttm)

    11.79%

  • Revenue (ttm)

    44.39B

  • Net Income Avi to Common (ttm)

    5.83B

  • Diluted EPS (ttm)

    0.1100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.22B

  • Total Debt/Equity (mrq)

    11.61%

  • Levered Free Cash Flow (ttm)

    4.13B

Research Analysis: R2WA.F

View More

People Also Watch